Abstract
The aim of the study was to establish and compare the efficacy and safety of sildenafil and apomorphine in men with arteriogenic erectile dysfunction (ED). In all, 43 men with ED and postinjection max penile systolic velocity <25 cm/s in repeated Doppler ultrasonography were included. Of these, 24 men started on apomorphine 2 mg and 19 on sildenafil 50 mg, the doses titrated up to 3 and 100 mg according to effectiveness and tolerability. Safety was evaluated according to adverse events (AEs) and patient withdrawal. Efficacy was the percentage of attempts resulting in erections firm enough for intercourse, based on event log data. The incidence of AEs with apomorphine 3 mg was higher than with sildenafil 100 mg. Two men on apomorphine 3 mg discontinued treatment due to AEs. The overall success rate of sildenafil was 63.7% compared to 32.1% of apomorphine (Pearson χ2, P<0.01). Of all men, 25 (58.1%) responded to sildenafil 50 mg without the need for dose increase, while only one responded to apomorphine 2 mg. The response to sildenafil 50 mg was age related (analysis of variance, p=0.04). Satisfaction was reported by 76.75 and 13.95% of patients for sildenafil and apomorphine, respectively, but 20.9% were not satisfied with any of the two drugs. In conclusion, this study provides clear evidence that sildenafil, even at 50 mg dose, is more effective than apomorphine 3 mg in men with arteriogenic ED. The fact that one out of five patients is not satisfied with the above-studied drugs shows that new oral agents need to be evaluated for the treatment of this disorder.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83–90.
Feldman HA et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.
Kaizer FE et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988; 36: 511–519.
Lee WH, Kim YC, Choi HK . Psychogenic versus primary organic impotence. Int J Impot Res 1994; 6: 93–97.
Nicolosi A et al. Diabetes and sexual function in older adults: results of an international survey. Br J Diabetes Vasc Dis 2002; 2: 336–339.
Nehra A et al. Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction. J Urol 1998; 159: 2229–2236.
Marks LS, Duda C, Dorey FJ . Treatment of erectile dysfunction with sildenafil. Urology 1999; 53: 19–24.
Montorsi F et al. Efficacy and safety of fixed-dose sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999; 53: 1011–1018.
Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397–1404.
Padma-Nathan H, Steers WD, Wicker PA, for the Sildenafil Study Group. Efficacy and safety of oral sildenafil in the treat-ment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998; 52: 375–379.
Boulton AJM et al. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 2001; 44: 1269–1301.
Hatzichristou D, Saenz de Tejada I, Sleep DJ, Perdok R . Time to erection with Uprim® (apomorphine SL) 2 and 3 mg in men with erectile dysfunction (ED). Int J Impot Res 2002; 13 (Suppl 4): S50.A140.
Stief C, Padley RJ, Perdok RJ, Sleep DJ . Cross-study review of the clinical efficacy of apomorphine 2 and 3 mg: pooled data from three placebo-controlled, fixed-dose crossover studies. Eur Urol 2002; (Suppl 1): 12–20.
Ralph DJ, Sleep DJ, Perdok RJ, Padley RJ . Adverse events and patient tolerability of apomorphine SL 2 and 3 mg: a cross-study analysis of phase II and phase III studies. Eur Urol 2002; (Suppl 1): 21–27.
Rosen RC et al. Development and evaluation of a bridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.
Lue TF . Impotence: a patient's goal-directed approach to treatment. World J Urol 1990; 8: 67–74.
Mirone VG, Stief CG . Efficacy of apomorphine SL in erectile dysfunction. Br J Urol Int 2001; 88 (Suppl 3): 25–29.
Carson CC et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60 (Suppl): 12–27.
Jarow JP, Burnett AL, Geringer AM . Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–725.
Martinez-Jabaloyas JM et al. Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol 2001; 40: 641–647.
Dula E, Bukofzer S, Perdok R, George M, The Apomorphine Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558–564.
Jarow JP, Patrick NS, Sabbagh M, Eskew A . Outcome analysis of goal-directed therapy for impotence. J Urol 1996; 155: 1609–1612.
Lue TF, Hricak H, Marich KW, Tanago EA . Vasculogenic impotence evaluated by high-resolution ultrasonography and pulsed Doppler spectrum analysis. Radiology 1985; 155: 777–781.
Broderick GA . Evidence based assessment of erectile dysfunction. Int J Impot Res 1998; 10 (Suppl 2): S64–S73.
Meuleman EJH et al. Penile pharmacological duplex ultrasonography: a dose-effect study comparing papaverine, papaverine/phentolamine and prostaglandin E1. J Urol 1992; 148: 63–66.
Akkus E et al. Repetition of color Doppler ultrasonography: is it necessary? Int J Impot Res 1998; 10: 51–55.
Rampin O . Mode of action of a new oral treatment for erectile dysfunction: apomorphine. Br J Urol Int 2001; 88 (Suppl 3): 22–24.
Wespes E et al. Guidelines on erectile dysfunction. Eur Urol 2002; 41: 1–5.
Cheithlin MD et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999; 99: 168–177.
Heart and Stroke Foundation of Canada and Canadian Cardiovascular Society. Managing sexual dysfunction: using sildenafil for patients with cardiovascular disease. Can Fam Phys 2000; 46: 393.
Heaton JPW, Hackett G, Savage D, Padley RJ . Patient choice is critical in managing erectile dysfunction. Eur Urol 2002; (Suppl 1): 33–37.
Adams MA, Perdok RJ, Padley RJ, Sleep DJ . Safety and tolerability of apomorphine SL in men with cardiovascular disorders. Eur Urol 2002; (Suppl 1): 28–32.
Bukofzer S, Livesey N . Safety and tolerability of apomorphine SL (Uprima®). Int J Impot Res 2001; 13 (Suppl 3): S40–S44.
Padma-Nathan H et al. A 4-year update on the safety of silde-nafil citrate (Viagra®). Urology 2002; 60 (Suppl 2B): 67–90.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perimenis, P., Gyftopoulos, K., Giannitsas, K. et al. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int J Impot Res 16, 2–7 (2004). https://doi.org/10.1038/sj.ijir.3901119
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901119
Keywords
This article is cited by
-
Erectile Dysfunction and Neurological Comorbidities: a Contemporary Review
Current Sexual Health Reports (2020)
-
Apomorphine for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis
Archives of Sexual Behavior (2020)
-
Clinical applications of centrally acting agents in male sexual dysfunction
International Journal of Impotence Research (2008)
-
Sildenafil combined with continuous positive airway pressure for treatment of erectile dysfunction in men with obstructive sleep apnea
International Urology and Nephrology (2007)
-
Erectile dysfunction in men with obstructive sleep apnea syndrome: a randomized study of the efficacy of sildenafil and continuous positive airway pressure
International Journal of Impotence Research (2004)